Looks at a PSMA scan in adults with glioblastoma receiving bevacizumab
Uses PSMA scans in adults with glioblastoma treated with bevacizumab.
Plain-language title generated from the registry record
Registry title: The Effect of Glioblastoma PSMA Expression Following Tumour VEGF Blockade From Bevacizumab
Key facts
- Where
- Saint Leonards, AustraliaSee the site
Where in Australia
- Royal North Shore HospitalSaint Leonards, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal North Shore Hospital
- Trial code
- NCT07052877
- Record updated
- 13 August 2026
- Original description
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.Read full original descriptionShow less
Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
Inclusion: > 18 year of age; ECOG 0-2; Able to provide informed consent for the study; Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour; Confirmed glioblastoma IDH1/2 wildtype (WHO2021); For bevacizumab treatment as per treating physician; Able to comply with trial requirements.
Exclusion: Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope; Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging; Does not fulfill PBS requirements for bevacizumab; No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment); Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study.